MINNEAPOLIS, Jan. 4, 2024
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today
announced it will present its portfolio of products and solutions
to enable cell and gene therapy development and manufacturing at
Phacilitate's Advanced Therapies Week, taking place January 16-19 at the Miami Beach Convention Center in Miami, Florida.
Bio-Techne's booth (#509) will feature its wide range of
products, services, and capabilities that enable cell and gene
therapy development and workflow solutions. These include the
non-viral gene editing TcBuster™ transposon system for immune cell
engineering, GMP media and liquid cytokines for immune cell
expansion, Fluorokines™ fluorescent labeled proteins and optimized
multi-color flow cytometry panels for CAR-T and CAR-NK cell
characterization, RNAscope™ in situ hybridization assays for
therapeutic visualization, and automated analytical instruments for
final product characterization and in vivo monitoring.
David Hermanson, Director for
Cell & Gene Therapy Applications at Bio-Techne, will present a
technical talk at the conference focusing on how gene modified cell
therapies can be manufactured at scale using the TcBuster
transposon system, specialty media, and liquid cytokines in the
G-Rex® bioreactor. Dr. Hermanson's talk will also
describe how automated Simple Plex™ immunoassays on Ella™ can be
used for the functional assessment of CAR-T cells. Dr. Hermanson's
presentation is scheduled to take place on Friday, January 19 at 10:00 AM EST.
"My presentation will be a wonderful opportunity for attendees
to learn how immune cell therapy development programs can benefit
from a streamlined T cell manufacturing workflow and licensable
transposon system for non-viral gene engineering," said Dr.
Hermanson.
ScaleReady, Bio-Techne's strategic partnership with Fresenius
Kabi and Wilson Wolf for integrated
immune cell therapy manufacturing workflow solutions, will also be
hosting a roundtable discussion bringing together industry leaders
to discuss the importance of scalable and cost-effective closed
system solutions for CAR-T cell manufacturing.
"In partnership with ScaleReady, Bio-Techne is proud to offer
flexible cell and gene therapy workflow solutions that simplify the
transition from RUO to GMP and allow for seamless process scale-up,
enabling our customers to get their therapies to the clinic with
speed and consistency," said Will
Geist, President of Bio-Techne's Protein Sciences
Segment.
Technical Talk:
Non-Viral Manufacturing of Gene Modified CAR T Therapies Using
TcBuster™
Presentation: Non-Viral Solutions for Gene Therapy
Friday, January 19th at
10:00AM EST, Theatre 2
Presenter: David Hermanson,
Ph.D.
Roundtable Talk:
Cell Therapy Manufacturing: A Look Under the Hood - Learning
from Outside the Industry. Can we make CAR-T cells like we make
cars? Thursday
Thursday, January 18th, at
8:00 AM EST, Theatre 2
- Josh Ludwig, Global Commercial
Director ScaleReady – Moderator
- Ignacio Nunez, Founder and CEO
BioExcellence LLC – Presenter and panelist
- Ricardo Jimenez, SVP Tech Ops at
Neurogene – Panelist
- Sarah Madonna, Sr Dir Manufacturing at Kiromic Biopharma –
Panelist
- Nick Casale, VP Global
Facilities & Corporate Engineering Ultragenyx Pharmaceutical –
Panelist
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated over $1.1
billion in net sales in fiscal 2023 and has approximately
3,100 employees worldwide. For more information on Bio-Techne and
its brands, please visit http://www.bio-techne.com or follow
the Company on social media at Facebook, LinkedIn, Twitter or
YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About ScaleReady
ScaleReady brings the future of cell and gene therapies to life
with its powerful and versatile manufacturing platform. Delivering
rapid expansion of immune cells at any scale—reducing complexity
and cost while providing superior repeatability and cell quality.
Founded in 2020, ScaleReady is a joint venture of Bio-Techne,
Fresenius Kabi, and Wilson Wolf that
brings together tools and technologies for cell culture, cell
activation, gene editing, and cell processing from each founding
partner. Learn more at www.scaleready.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-showcase-cell-and-gene-therapy-manufacturing-tools-at-phacilitate-advanced-therapies-week-2024-302025136.html
SOURCE Bio-Techne Corporation